The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Potanin S.S.

Centre for Mental Health Research

Morozova M.A.

Centre for Mental Health Research

Oxidative stress in schizophrenia as a promising target for psychopharmacotherapy

Authors:

Potanin S.S., Morozova M.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9): 131‑138

DOI: 10.17116/jnevro2021121091131

Read: 4396 times

Contact the author
Table of contents

OXIDATIVE STRESS IN SCHIZOPHRENIA AS A PROMISING TARGET FOR PSYCHOPHARMACOTHERAPY
OXIDATIVE STRESS IN SCHIZOPHRENIA AS A PROMISING TARGET FOR PSYCHOPHARMACOTHERAPY

To cite this article:

Potanin SS, Morozova MA. Oxidative stress in schizophrenia as a promising target for psychopharmacotherapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(9):131‑138. (In Russ.)
https://doi.org/10.17116/jnevro2021121091131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Until now, only dopamine receptor blockers are used for psychopharmacotherapy of schizophrenia, despite the active search for alternative pharmacological agents and a lot of research. However, most of these studies concerned molecules that somehow affect various neurotransmitter receptors. In addition, various anti-inflammatory drugs have been studied quite actively. At the same time, attempts to correct oxidative stress are given significantly less attention, although the emergence of the latter is facilitated by completely different pathophysiological processes and environmental factors associated with the development of schizophrenia. NMDA receptor blockage, vitamin D deficiency, social isolation, chronic stress in adolescence, inflammation, perinatal infection etc. — all this can ultimately lead to the occurrence of oxidative stress. However, there is a significant difference in the severity of this process depending on the stage of the course of schizophrenia, which probably partially explains the heterogeneity of results of the studies on the oxidative stress biomarkers in this disorder. In order to overcome these methodological problems, it seems promising to conduct double-blind studies of the effectiveness of antioxidants in schizophrenia with the selection of groups of patients taking into account the stage of the disorder and the level of certain biomarkers of oxidative stress (F2-isoprostanes, 8-oxodG, 8-oxoGuo). The optimal pharmacological agents for such studies are N-acetylcysteine due to the positive results of previous studies, and melatonin as an antioxidant with a unique activity profile.

Keywords:

schizophrenia
oxidative stress
pathophysiology of schizophrenia
psychopharmacotherapy of schizophrenia

Authors:

Potanin S.S.

Centre for Mental Health Research

Morozova M.A.

Centre for Mental Health Research

Received:

17.07.2020

Accepted:

10.03.2021

Close metadata

References:

  1. Bruijnzeel D, Suryadevara U, Tandon R. Antipsychotic treatment of schizophrenia: An update. Asian Journal of Psychiatry. 2014;11:3-7.  https://doi.org/10.1016/j.ajp.2014.08.002
  2. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology. 2019;29(9):971-985.  https://doi.org/10.1016/j.euroneuro.2019.06.008
  3. Mongan D, Ramesar M, Föcking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Intervention in Psychiatry. 2019;14(4):385-397.  https://doi.org/10.1111/eip.12859
  4. Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophrenia Research. 2016;176(1):52-71.  https://doi.org/10.1016/j.schres.2015.06.022
  5. Cho M, Lee TY, Kwak YB, Yoon YB, Kim M, Kwon JS. Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry. 2019;53(8):742-759.  https://doi.org/10.1177/0004867419835028
  6. Klann E, Roberson ED, Knapp LT, Sweatt JD. A role for superoxide in protein kinase C activation and induction of long-term potentiation. J Biol Chem. 1998;273(8):4516-4522. https://doi.org/10.1074/jbc.273.8.4516
  7. Wood SJ, Berger GE, Wellard RM, Proffitt T-M, McConchie M, Berk M, McGorry PD, Pantelis C. Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation. Neurobiology of Disease. 2009;33(3):354-357.  https://doi.org/10.1016/j.nbd.2008.11.018
  8. Sies H, Berndt C, Jones DP. Oxidative Stress. Annual Review of Biochemistry. 2017;86(1):715-748.  https://doi.org/10.1146/annurev-biochem-061516-045037
  9. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin e supplementation may increase all-cause mortality. Annals of Internal Medicine. 2005;142(1):37-46.  https://doi.org/10.7326/0003-4819-142-1-200501040-00110
  10. Beckhauser TF, Francis-Oliveira J, De Pasquale R. Reactive oxygen species: physiological and physiopathological effects on synaptic plasticity: supplementary issue: brain plasticity and repair. J Exp Neurosci. 2016;10s1:JEN.S39887. https://doi.org/10.4137/JEN.S39887
  11. Сыровая А.О., Леонтьева Ф.С., Новикова И.В., Иванникова С.В. Биологическая роль свободных радикалов в развитии патологических состояний. Международный медицинский журнал. 2012;3:98-104. 
  12. Iglesias J, Pazos M, Torres JL., Medina I. Antioxidant mechanism of grape procyanidins in muscle tissues: Redox interactions with endogenous ascorbic acid and α-tocopherol. Food Chemistry. 2012;134(4):1767-1774. https://doi.org/10.1016/j.foodchem.2012.03.072
  13. Radak Z, Zhao Z, Goto S, Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Molecular Aspects of Medicine. 2011;32(4):305-315.  https://doi.org/10.1016/j.mam.2011.10.010
  14. Haigis MC, Yankner BA. The Aging Stress Response. Molecular Cell. 2010;40(2):333-344.  https://doi.org/10.1016/j.molcel.2010.10.002
  15. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, «just the facts»: What we know in 2008: Part 3: Neurobiology. Schizophrenia Research. 2008;106(2-3):89-107.  https://doi.org/10.1016/j.schres.2008.07.020
  16. Frohlich J, Van Horn JD. Reviewing the ketamine model for schizophrenia. J Psychopharmacol. 2014;28(4):287-302.  https://doi.org/10.1177/0269881113512909
  17. Zuo D-Y, Wu Y-L, Yao W-X, Cao Y, Wu C-F, Tanaka M. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Biochem Behav. 2007;86(1):1-7.  https://doi.org/10.1016/j.pbb.2006.05.010
  18. de Carvalho Lima CN, Doifode T, Colodel A, Sayana P, Giridharan VV, Macedo DS, Pinjari OF, Barichello T. Maternal immune activation as a risk factor for schizophrenia: evidence from preclinical and clinical studies. In: Teixeira A.L., Macedo D., Baune B.T., eds. Perinatal Inflammation and Adult Psychopathology: From Preclinical Models to Humans. Progress in Inflammation Research. Cham: Springer International Publishing; 2020;129-154.  https://doi.org/10.1007/978-3-030-39335-9_9
  19. Ribeiro BMM, do Carmo MRS, Freire RS, Rocha NFM, Borella VCM, de Menezes AT, Monte AS, Gomes PXL, de Sousa FCF, Vale ML, de Lucena DF, Gama CS, Macêdo D. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine. Schizophrenia Research. 2013;151(1):12-19.  https://doi.org/10.1016/j.schres.2013.10.040
  20. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456-1458. https://doi.org/10.1126/science.1202529
  21. Mallya AP, Wang H-D, Lee HNR, Deutch AY. Microglial pruning of synapses in the prefrontal cortex during adolescence. Cerebral Cortex. 2019;29(4):1634-1643. https://doi.org/10.1093/cercor/bhy061
  22. Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490-503.  https://doi.org/10.1016/j.redox.2018.01.008
  23. Howes OD, McCutcheon R, Owen MJ, Murray R. The role of genes, stress and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9-20.  https://doi.org/10.1016/j.biopsych.2016.07.014
  24. Deslauriers J, Racine W, Sarret P, Grignon S. Preventive effect of α-lipoic acid on prepulse inhibition deficits in a juvenile two-hit model of schizophrenia. Neuroscience. 2014;272:261-270.  https://doi.org/10.1016/j.neuroscience.2014.04.061
  25. Jiang Z, Rompala GR, Zhang S, Cowell RM, Nakazawa K. Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biological Psychiatry. 2013;73(10):1024-1034. https://doi.org/10.1016/j.biopsych.2012.12.004
  26. Möller M, Du Preez JL, Viljoen FP, Berk M, Emsley R, Harvey BH. Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain, Behavior, and Immunity. 2013;30:156-167.  https://doi.org/10.1016/j.bbi.2012.12.011
  27. Chowdari KV, Bamne MN, Nimgaonkar VL. Genetic Association Studies of Antioxidant Pathway Genes and Schizophrenia. Antioxid Redox Signal. 2011;15(7):2037-2045. https://doi.org/10.1089/ars.2010.3508
  28. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuénod M, Do KQ. Impaired glutathione synthesis in schizophrenia: Convergent genetic and functional evidence. PNAS. 2007;104(42):16621-16626. https://doi.org/10.1073/pnas.0706778104
  29. Gravina P, Spoletini I, Masini S, Valentini A, Vanni D, Paladini E, Bossù P, Caltagirone C, Federici G, Spalletta G, Bernardini S. Genetic polymorphisms of glutathione S-transferases GSTM1, GSTT1, GSTP1 and GSTA1 as risk factors for schizophrenia. Psychiatry Research. 2011;187(3):454-456.  https://doi.org/10.1016/j.psychres.2010.10.008
  30. Rodríguez-Santiago B, Brunet A, Sobrino B, Serra-Juhé C, Flores R, Armengol L, Vilella E, Gabau E, Guitart M, Guillamat R, Martorell L, Valero J, Gutiérrez-Zotes A, Labad A, Carracedo A, Estivill X, Pérez-Jurado LA. Association of common copy number variants at the glutathione S -transferase genes and rare novel genomic changes with schizophrenia. Molecular Psychiatry. 2010;15(10):1023-1033. https://doi.org/10.1038/mp.2009.53
  31. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, Matthey M-L, Parnas J, Preisig M, Saraga M, Solida A, Timm S, Wang AG, Werge T, Cuénod M, Do KQ. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. The American Journal of Human Genetics. 2006;79(3):586-592.  https://doi.org/10.1086/507566
  32. Ben-Shachar D. Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target. Schizophrenia Research. 2017;187:3-10.  https://doi.org/10.1016/j.schres.2016.10.022
  33. Dror N, Klein E, Karry R, Sheinkman A, Kirsh Z, Mazor M, Tzukerman M, Ben-Shachar D. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry. 2002;7(9):995-1001. https://doi.org/10.1038/sj.mp.4001116
  34. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry and Clinical Neurosciences. 2009;63(3):257-265.  https://doi.org/10.1111/j.1440-1819.2009.01945.x
  35. Ramana KV, Srivastava SK. Aldose reductase: A novel therapeutic target for inflammatory pathologies. The International Journal of Biochemistry & Cell Biology. 2010;42(1):17-20.  https://doi.org/10.1016/j.biocel.2009.09.009
  36. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry. 2007;7(1):46.  https://doi.org/10.1186/1471-244X-7-46
  37. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Progress in Neurobiology. 2011;93(1):13-24.  https://doi.org/10.1016/j.pneurobio.2010.09.004
  38. Maas DA, Vallès A, Martens GJM. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Translational Psychiatry. 2017;7(7):e1171-e1171. https://doi.org/10.1038/tp.2017.138
  39. Cantor-Graae E, Pedersen CB. Risk of schizophrenia in second-generation immigrants: a Danish population-based cohort study. Psychological Medicine. 2007;37(4):485-494.  https://doi.org/10.1017/S0033291706009652
  40. Mortensen PB, Pedersen CB, Westergaard T, Wohlfahrt J, Ewald H, Mors O, Andersen PK, Melbye M. Effects of family history and place and season of birth on the risk of schizophrenia. New England Journal of Medicine. 1999;340(8):603-608.  https://doi.org/10.1056/NEJM199902253400803
  41. McGrath J, Eyles D, Mowry B, Yolken R, Buka S. Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophrenia Research. 2003;63(1):73-78.  https://doi.org/10.1016/S0920-9964(02)00435-8
  42. Codoñer-Franch P, Tavárez-Alonso S, Simó-Jordá R, Laporta-Martín P, Carratalá-Calvo A, Alonso-Iglesias E. Vitamin d status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. The Journal of Pediatrics. 2012;161(5):848-854.  https://doi.org/10.1016/j.jpeds.2012.04.046
  43. Puchacz E, Stumpf WE, Stachowiak EK, Stachowiak MK. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res. 1996;36(1):193-196.  https://doi.org/10.1016/0169-328x(95)00314-i
  44. Enwright JF, Sanapala S, Foglio A, Berry R, Fish KN, Lewis DA. Reduced labeling of parvalbumin neurons and perineuronal nets in the dorsolateral prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology. 2016;41(9):2206-2214. https://doi.org/10.1038/npp.2016.24
  45. Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biological Psychiatry. 2015;77(12):1031-1040. https://doi.org/10.1016/j.biopsych.2015.03.010
  46. Steullet P, Cabungcal J-H, Coyle J, Didriksen M, Gill K, Grace AA, Hensch TK, LaMantia A-S, Lindemann L, Maynard TM, Meyer U, Morishita H, O’Donnell P, Puhl M, Cuenod M, Do KQ. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Molecular Psychiatry. 2017;22(7):936-943.  https://doi.org/10.1038/mp.2017.47
  47. Maas DA, Vallès A, Martens GJM. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Translational Psychiatry. 2017;7(7):e1171-e1171. https://doi.org/10.1038/tp.2017.138
  48. Dietrich-Muszalska A, Kopka J, Kwiatkowska A. The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison. Neurochem Res. 2013;38(7):1490-1495. https://doi.org/10.1007/s11064-013-1050-z
  49. Bošković M, Grabnar I, Terzič T, Kores Plesničar B, Vovk T. Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. Psychiatry Res. 2013;210(3):761-768.  https://doi.org/10.1016/j.psychres.2013.08.035
  50. Bachaldina E.N., Gavrilov S.S., Kulinskij V.I. Vliyanie tipichnogo i atipichnogo nejroleptikov na aktivnost’ glutationtransferazy golovnogo mozga. Palliativnaya medicina i reabilitaciya. 2006;(2). https://www.elibrary.ru/item.asp?id=9250373
  51. Lepping P, Delieu J, Mellor R, Williams JHH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry. 2011;72(3):273-285.  https://doi.org/10.4088/JCP.09r05268yel
  52. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett. 2004;372(1-2):157-160.  https://doi.org/10.1016/j.neulet.2004.09.032
  53. Libin L.YA., Ivanov M.V., Eshchenko N.D., Lesnikova S.A., Dagaev S.G. K voprosu izucheniya mekhanizmov razvitiya oksidativnogo stressa u bol’nyh paranoidnoj pristupoobraznoj shizofreniej, poluchayushchih antipsihoticheskuyu terapiyu. Psihiatriya i psihofarmakoterapiya. 2012;14(5). https://www.elibrary.ru/item.asp?id=18903520
  54. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22(1-2):83-93.  https://doi.org/10.1155/2006/248387
  55. Gawryluk JW, Wang J-F, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14(1):123-130.  https://doi.org/10.1017/S1461145710000805
  56. Altuntas I, Aksoy H, Coskun I, Cayköylü A, Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med. 2000;38(12):1277-1281. https://doi.org/10.1515/CCLM.2000.201
  57. Dietrich-Muszalska A, Olas B, Głowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology. 2009;59(1):1-7.  https://doi.org/10.1159/000202822
  58. Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA. 2005;18(5):276.  https://doi.org/10.1007/s10334-005-0012-0
  59. Samuelsson M, Skogh E, Lundberg K, Vrethem M, Öllinger K. Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia. Psychiatry Research. 2013;210(3):819-824.  https://doi.org/10.1016/j.psychres.2013.09.014
  60. Vil’yanov V.B., Kolesnichenko E.V., Zaharova N.B., Nikitina V.V. Pokazateli oksidativnogo stressa u bol’nyh paranoidnoj shizofreniej. Klinicheskaya laboratornaya diagnostika. 2005;(9). https://www.elibrary.ru/item.asp?id=17023523
  61. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology. 2005;182(4):494-498.  https://doi.org/10.1007/s00213-005-0117-1
  62. Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust N Z J Psychiatry. 1999;33(1):84-88.  https://doi.org/10.1046/j.1440-1614.1999.00527.x
  63. Firth J, Stubbs B, Sarris J, Rosenbaum S, Teasdale S, Berk M, Yung AR. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis. Psychological Medicine. 2017;47(9):1515-1527. https://doi.org/10.1017/S0033291717000022
  64. Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research. 2002;36(1):7-18.  https://doi.org/10.1016/S0022-3956(01)00048-6
  65. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. Journal of Clinical Psychopharmacology. 2012;32(2):179-185.  https://doi.org/10.1097/JCP.0b013e318248b7bb
  66. Марута Н.А., Рачкаускас Г.С., Фролов В.М., Терешина И.Ф. Эффективность комбинации циклоферона и реамбирина при лечении терапевтически резистентных больных параноидной шизофренией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(12):36-39. 
  67. Kut’ko I.I., Frolov V.M., Rachkauskas G.S., Radionova S.I. Ocenka effektivnosti reamberina pri febril’noj shizofrenii. Tavricheskij Zhurnal Psihiatrii. 2012;16(4 (61)). https://www.elibrary.ru/item.asp?id=24795367
  68. Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM. Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2015;57:69-75.  https://doi.org/10.1016/j.pnpbp.2014.10.002
  69. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial. Biological Psychiatry. 2008;64(5):361-368.  https://doi.org/10.1016/j.biopsych.2008.03.004
  70. Reiter RJ, Rosales-Corral S, Tan DX, Jou MJ, Galano A, Xu B. Melatonin as a mitochondria-targeted antioxidant: one of evolution’s best ideas. Cell Mol Life Sci. 2017;74(21):3863-3881. https://doi.org/10.1007/s00018-017-2609-7
  71. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58(11):1049-1052. https://doi.org/10.1001/archpsyc.58.11.1049
  72. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? The Journal of Clinical Psychiatry. 2000;61:556-558.  https://doi.org/10.4088/JCP.v61n0803
  73. Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(2):237-241.  https://doi.org/10.4088/jcp.v68n0208
  74. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61(5):373-377.  https://doi.org/10.4088/jcp.v61n0509
  75. Dietrich-Muszalska DA, Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. The World Journal of Biological Psychiatry. 2009;10(1):27-33.  https://doi.org/10.1080/15622970701361263
  76. Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HHHW, Ghezzi P. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal. 2015;23(14):1144-1170. https://doi.org/10.1089/ars.2015.6317
  77. Pyatojkina A.S., ZHilyaeva T.V., Blagonravova A.S., Mazo G.E. N-acetilcistein kak metod personificirovannoj korrekcii redoksdisbalansa u pacientov s pervym epizodom shizofrenii. Psihiatriya i psihofarmakoterapiya. 2019;21(5). https://www.elibrary.ru/item.asp?id=42558674
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.